I. Staropoli

Recapitulating memory B cell responses in a Lymphoid Organ-Chip to evaluate mRNA vaccine boosting strategies

The paper develops a Lymphoid Organ-Chip to evaluate mRNA vaccine boosting strategies by mimicking immune responses to SARS-CoV-2 Spike protein and comparing monovalent and bivalent vaccines.

Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion

This study characterizes SARS-CoV-2 variants XBB and BA.2.86/JN.1, finding they show increased fitness and antibody evasion while maintaining antiviral sensitivity.

High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1

This study characterizes the high fusogenicity and cytopathic effects of the SARS-CoV-2 B.1.640.1 variant, identifying mutations in the spike S2 domain responsible for these properties.

Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies

This study evaluates the neutralizing antibody resistance of SARS-CoV-2 Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to monoclonal antibodies and sera from vaccinated individuals.

The spike-stabilizing D614G mutation interacts with S1/S2 cleavage site mutations to promote the infectious potential of SARS-CoV-2 variants

This study shows the D614G mutation enhances the infectious potential of SARS-CoV-2 variants by synergizing with cleavage site mutations like P681H/R to increase spike fusogenicity.

Potent Human Broadly SARS-CoV-2 Neutralizing IgA and IgG Antibodies Effective Against Omicron BA.1 and BA.2

The paper identifies potent broadly neutralizing IgA and IgG antibodies against SARS-CoV-2 variants, including Omicron BA.1 and BA.2, from memory B cells in convalescents.

Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2

This study examines the fusogenicity and neutralization sensitivity of the SARS-CoV-2 AY.4.2 sublineage compared to the Delta variant, finding similar spike function but reduced neutralization sensitivity to certain antibodies and vaccines.

Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization

This study shows that the Omicron variant of SARS-CoV-2 is resistant to most monoclonal antibodies and vaccine-induced antibodies, with reduced neutralization compared to Delta.

Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals

This study shows that the SARS-CoV-2 B.1.617.2 variant is less sensitive to monoclonal antibodies and sera from convalescent and vaccinated individuals compared to other variants.

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

This study assesses the neutralization sensitivity of SARS-CoV-2 B.1.1.7 and B.1.351 variants compared to D614G using sera and nasal swabs, finding reduced efficacy against B.1.351 in some convalescent and vaccinated individuals.